HCA Healthcare, Inc. HCA
Verdict: Hold. Fair value $461 against a price of $478 on 6 Jan 2026, 3% below the price.
In plain words
The case for: Narrow competitive moat provides durability. Market leadership enables pricing power. Industry tailwinds with growing market.
The case against: Net Income peaked significantly at $6.96B in 2021, an 85% increase from 2020, before declining to....
Main risks
- Negative Stockholders' Equity (-$2.50B): This is a severe balance sheet red flag, indicating that liabilities exceed assets on a book basis. It renders ROE and Debt-to-Equity ratios meaningless and suggests aggressive capital returns (e.g., buybacks) funded by debt, increasing financial risk.
- Missing Total Debt Data: The inability to calculate key leverage ratios (Debt/Equity, Net Debt/EBITDA) creates a major blind spot in assessing the company's solvency and financial risk, which is particularly concerning given the negative equity.
- High Capital Expenditures with Unproven Returns: TTM CapEx is substantial at $4.74B. While the estimated 3-year ROIIC of 13.9% is good, this calculation relies on several proxies due to missing historical data, making the true return on this significant investment uncertain.
- Market volatility
- Execution risk
- Macroeconomic uncertainty